Dianthin and Its Potential in Targeted Tumor Therapies

Toxins

Hendrik Fuchs¹ 

[1] Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health;

关键词: dianthin;    ribosome-inactivating protein;    targeted toxin;    immunotoxin;    endosomal escape;    cancer therapy;    dianthus caryophyllus l.;   

DOI  :  10.3390/toxins11100592

来源: DOAJ

【 摘 要 】

Dianthin enzymes belong to ribosome-inactivating proteins (RIPs) of type 1, i.e., they only consist of a catalytic domain and do not have a cell binding moiety. Dianthin-30 is very similar to saporin-S3 and saporin-S6, two RIPs often used to design targeted toxins for tumor therapy and already tested in some clinical trials. Nevertheless, dianthin enzymes also exhibit differences to saporin with regard to structure, efficacy, toxicity, immunogenicity and production by heterologous expression. Some of the distinctions might make dianthin more suitable for targeted tumor therapies than other RIPs. The present review provides an overview of the history of dianthin discovery and illuminates its structure, function and role in targeted toxins. It further discusses the option to increase the efficacy of dianthin by endosomal escape enhancers.

【 授权许可】

Unknown